MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway

BACKGROUND: Although cisplatin is an effective chemotherapeutic drug that is commonly used for non-small-cell lung cancer (NSCLC) treatment, the drug resistance usually occurs during the long-term use of it. It is urgent to develop strategies to reduce the resistance of NSCLC cells to cisplatin. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zhilai, Pan, Jianguang, Chen, Lei, Wang, Xinhang, Chen, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443038/
https://www.ncbi.nlm.nih.gov/pubmed/32884297
http://dx.doi.org/10.2147/OTT.S261799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443038/
https://www.ncbi.nlm.nih.gov/pubmed/32884297
http://dx.doi.org/10.2147/OTT.S261799

Ejemplares similares